Modulating Trem2 signaling through Trem2 antagonistic antibodies can alter microglia function and cause disease-relevant changes in Alzheimer’s disease.
Investigating the symmetry of fibrillar plaques on AD mouse models confirms an asymmetric pattern, similar to Alzheimer’s disease patients, which translated into regional microglia activation.
